Antisense approaches in prostate cancer (Q35790875)

10 August 2017

1 reference

title

Antisense approaches in prostate cancer (English)

1 reference

10 August 2017

1 reference

Kim N Chi

1

1 reference

PubMed ID

15174974

10 August 2017

Martin E Gleave

series ordinal

2

1 reference

PubMed ID

15174974

10 August 2017

language of work or name

English

0 references

publication date

1 June 2004

1 reference

Expert Opinion on Biological Therapy

10 August 2017

1 reference

10 August 2017

4

1 reference

10 August 2017

6

1 reference

10 August 2017

927-936

1 reference

10 August 2017

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

Molecular mechanisms of antisense drugs: RNase H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

Regulation of prostatic growth and function by peptide growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

The development of androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

Bcl-2 and the regulation of programmed cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

Overexpression of clusterin in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

Gp80 (clusterin; TRPM-2) mRNA level is enhanced in human renal clear cell carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

Clusterin is a secreted mammalian chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

Stress-induced transcription of the clusterin/apoJ gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

X-linked IAP is a direct inhibitor of cell-death proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

The anti-apoptotic activity of XIAP is retained upon mutation of both the caspase 3- and caspase 9-interacting sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

IAP proteins: blocking the road to death's door

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

Abnormal expression of MDM2 in prostate carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

MDM2 induces NF-kappaB/p65 expression transcriptionally through Sp1-binding sites: a novel, p53-independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

Regulation of protein kinase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

Specific block of androgen receptor activity by antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

Clusterin Has Chaperone-like Activity Similar to That of Small Heat Shock Proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.927

21 January 2018

Identifiers

DOI

10.1517/14712598.4.6.927

1 reference

10 August 2017

1 reference

PubMed ID

15174974